EARLY DIAGNOSTIC CRITERIA OF RENAL INJURY AND COORDINATION OF TREATMENT IN PATIENTS WITH CHRONIC HEART FAILURE

Atakhodjayeva G. A.; Korakulova Z.T.

doi:10.61796/jmgcb.v2i12.1467

Authors

Atakhodjayeva G. A.
atakhodjaeva79@gmail.com
Tashkent State Medical University, Uzbekistan
Korakulova Z.T. Tashkent State Medical University, Uzbekistan

Vol. 2 No. 12 (2025): Journal of Medical Genetics and Clinical Biology

Articles

September 15, 2025

Downloads

PDF

Abstract
How to Cite
Metrics
References
License

Objective: This study aimed to examine the clinical, functional, echocardiographic, and biomarker characteristics of chronic heart failure (CHF) patients with and without renal dysfunction, given the frequent coexistence of both conditions and their complex management challenges. Method: A total of 129 CHF patients were evaluated and divided into two groups based on renal function. Clinical symptoms, six-minute walk test results, echocardiographic findings, and serum biomarker levels were compared. Results: Patients with renal dysfunction exhibited more severe symptoms, higher Clinical State Scale scores, shorter walking distances, and more advanced diastolic failure with greater ventricular remodeling. NT-proBNP, NGAL, KIM-1, and cystatin C levels were significantly elevated in the renal dysfunction group, whereas creatinine showed only minor increases. This discrepancy indicates the limited sensitivity of traditional renal markers in detecting early tubular injury. Novelty: The study highlights the diagnostic value of novel renal biomarkers in CHF patients, demonstrating their potential for early detection of subclinical kidney damage and improved risk stratification, ultimately contributing to timely interventions and better prognostic outcomes.

G. A., A., & Z.T. , K. (2025). EARLY DIAGNOSTIC CRITERIA OF RENAL INJURY AND COORDINATION OF TREATMENT IN PATIENTS WITH CHRONIC HEART FAILURE. Journal of Medical Genetics and Clinical Biology, 2(12), 584–592. https://doi.org/10.61796/jmgcb.v2i12.1467

Download Citation

G. Savarese and L. H. Lund, "Global public health burden of heart failure," Card Fail Rev., vol. 3, no. 1, pp. 7–11, 2017, doi: 10.15420/cfr.2016:25:2.

C. Ronco, M. Haapio, A. A. House, N. Anavekar, and R. Bellomo, "Cardiorenal syndrome," J. Am. Coll. Cardiol., vol. 52, no. 19, pp. 1527–1539, 2008, doi: 10.1016/j.jacc.2008.07.051.

S. G. Coca and C. R. Parikh, "Urinary biomarkers for acute kidney injury: perspectives on translation," Clin. J. Am. Soc. Nephrol., vol. 3, no. 2, pp. 481–490, 2008, doi: 10.2215/CJN.03740907.

I. C. Kuo, J. C. Huang, P. Y. Wu, S. C. Chen, J. M. Chang, and H. C. Chen, "Comparison of BTP, NGAL, KIM-1, and ADMA in chronic kidney disease and non-CKD subjects," Sci. Rep., vol. 9, no. 1, pp. 1–9, 2019, doi: 10.1038/s41598-019-42015-6.

M. C. Foster, L. A. Inker, A. S. Levey, E. Selvin, J. Eckfeldt, S. P. Juraschek, et al., "Novel filtration markers as predictors of incident CKD stage 3: the ARIC study," Am. J. Kidney Dis., vol. 65, no. 3, pp. 510–518, 2015, doi: 10.1053/j.ajkd.2014.09.016.

C. C. J. Dekkers, D. C. Wheeler, C. D. Sjöström, B. V. Stefansson, V. Cain, and H. J. L. Heerspink, "Effects of the SGLT2 inhibitor dapagliflozin on glomerular and tubular injury markers," Diabetes Obes. Metab., vol. 20, no. 8, pp. 1988–1993, 2018, doi: 10.1111/dom.13309.

F. Zannad, J. P. Ferreira, S. J. Pocock, S. D. Anker, J. Butler, G. Filippatos, et al., "SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a review of the evidence on interleukin-6 and outcomes," JACC Heart Fail., vol. 8, no. 6, pp. 512–525, 2020, doi: 10.1016/j.jchf.2020.01.014.

G. Savarese, D. Stolfo, G. Sinagra, and L. H. Lund, "Heart failure with mid-range or preserved ejection fraction: different phenotypes, similar outcomes?," Eur. J. Heart Fail., vol. 21, no. 1, pp. 14–24, 2019, doi: 10.1002/ejhf.1373.

V. Y. Mareev, I. V. Fomin, F. T. Ageev, Y. L. Begrambekova, Y. A. Vasyuk, A. A. Garganeeva, et al., "Clinical guidelines for chronic heart failure diagnosis and management," Kardiologiia, vol. 58, no. 6S, pp. 8–158, 2018, doi: 10.18087/cardio.2475.

M. G. Shlipak, K. Matsushita, J. Ärnlöv, L. A. Inker, R. Katz, K. R. Polkinghorne, et al., "Cystatin C versus creatinine in determining risk based on kidney function," N. Engl. J. Med., vol. 369, no. 10, pp. 932–943, 2013, doi: 10.1056/NEJMoa1214234.

T. L. Nickolas, K. M. Schmidt-Ott, P. Canetta, C. Forster, E. Singer, M. Sise, et al., "Diagnostic and prognostic stratification using urinary biomarkers of nephron damage," J. Am. Coll. Cardiol., vol. 59, no. 3, pp. 246–255, 2012, doi: 10.1016/j.jacc.2011.10.854.

K. Damman, M. A. Valente, A. A. Voors, C. M. O’Connor, D. J. van Veldhuisen, and H. L. Hillege, "Renal impairment, worsening renal function, and outcome in patients with heart failure," Eur. Heart J., vol. 35, no. 7, pp. 455–469, 2014, doi: 10.1093/eurheartj/eht386.

P. A. McCullough, R. M. Nowak, C. Foreback, J. McCord, M. P. Hudson, M. C. Tomlanovich, et al., "B-type natriuretic peptide and renal function in the diagnosis of heart failure: an analysis from the Breathing Not Properly Multinational Study," Am. J. Kidney Dis., vol. 41, no. 3, pp. 571–579, 2003, doi: 10.1053/ajkd.2003.50116.

D. Bolignano, V. Donato, G. Coppolino, S. Campo, A. Buemi, A. Lacquaniti, et al., "Neutrophil gelatinase-associated lipocalin (NGAL) as an early biomarker of kidney damage in chronic kidney disease," Kidney Int., vol. 73, no. 5, pp. 495–502, 2008, doi: 10.1038/sj.ki.5002711.

W. K. Han, V. Bailly, R. Abichandani, R. Thadhani, and J. V. Bonventre, "Kidney Injury Molecule-1 (KIM-1): a novel biomarker for human renal proximal tubule injury," Kidney Int., vol. 62, no. 1, pp. 237–244, 2002, doi: 10.1046/j.1523-1755.2002.00433.x.

C. Ronco, M. Haapio, A. A. House, N. Anavekar, and R. Bellomo, "Cardiorenal syndrome," J. Am. Coll. Cardiol., vol. 52, no. 19, pp. 1527–1539, 2008, doi: 10.1016/j.jacc.2008.07.051.

M. C. Foster, J. Coresh, C. Y. Hsu, D. Xie, A. S. Levey, R. G. Nelson, et al., "Serum and urine biomarkers as predictors of kidney disease: the ARIC study," J. Am. Soc. Nephrol., vol. 26, no. 8, pp. 1981–1991, 2015, doi: 10.1681/ASN.2014070642.

C. C. J. Dekkers, S. Petrykiv, G. D. Laverman, D. Z. I. Cherney, R. T. Gansevoort, and H. J. L. Heerspink, "Effects of the SGLT-2 inhibitor dapagliflozin on glomerular and tubular injury markers," Diabetes Obes. Metab., vol. 20, no. 8, pp. 1988–1993, 2018, doi: 10.1111/dom.13205.

H. J. L. Heerspink, B. V. Stefansson, R. Correa-Rotter, G. M. Chertow, T. Greene, F. F. Hou, et al., "Dapagliflozin in patients with chronic kidney disease," N. Engl. J. Med., vol. 383, no. 15, pp. 1436–1446, 2020, doi: 10.1056/NEJMoa2024816.